Nonhuman Primate in Nonclinical Drug Development and Safety Assessment (eBook)

Joerg Bluemel, Sven Korte, Emanuel Schenck, Gerhard Weinbauer (Herausgeber)

eBook Download: PDF | EPUB

2015 | 1. Auflage
716 Seiten
Elsevier Science (Verlag)
978-0-12-417146-6 (ISBN)

Infos

The Nonhuman Primate in Drug Development and Safety Assessment is a valuable reference dedicated to compiling the latest research on nonhuman primate models in nonclinical safety assessment, regulatory toxicity testing and translational science. By covering important topics such as study planning and conduct, inter-species genetic drift, pathophysiology, animal welfare legislation, safety assessment of biologics and small molecules, immunotoxicology and much more, this book provides scientific and technical insights to help you safely and successfully use nonhuman primates in pharmaceutical toxicity testing. A comprehensive yet practical guide, this book is intended for new researchers or practicing toxicologists, toxicologic pathologists and pharmaceutical scientists working with nonhuman primates, as well as graduate students preparing for careers in this area. - Covers important topics such as species selection, study design, experimental methodologies, animal welfare and the 3Rs (Replace, Refine and Reduce), social housing, regulatory guidelines, comparative physiology, reproductive biology, genetic polymorphisms and more - Includes practical examples on techniques and methods to guide your daily practice - Offers a companion website with high-quality color illustrations, reference values for safety assessment and additional practical information such as study design considerations, techniques and procedures and dosing and sampling volumes

Textauszug

Contributors

Paul Barrow     F. Hoffmann-La Roche Ltd., Basel, Switzerland

Kathryn Bayne     AAALAC International, Frederick, MD, USA

Joerg Bluemel     MedImmune, Gaithersburg, MD, USA

Frank Brennan     UCB Pharma, New Medicines, Non-Clinical Development, Slough, UK

Iris D. Bolton     University of Texas Medical Branch, Galveston, TX, USA

Christopher J. Bowman     Pfizer Inc., Groton, CT, USA

Wayne R. Buck     AbbVie, Inc., North Chicago, IL, USA

Leigh Ann Burns-Naas     Gilead Sciences, Inc., Foster City, CA, USA

David B. Burr     Lilly Research Laboratories, Indianapolis, IN, USA

Jennifer A. Cann     MedImmune, Gaithersburg, MD, USA

Annick J. Cauvin     UCB Biopharma, New Medicine, Non-Clinical Development, Braine L’Alleud, Belgium

Joy A. Cavagnaro     Access BIO, Boyce, VA, USA

Ulrich Certa     F. Hoffmann–La Roche Ltd, Pharma Research & Early Development, Basel, Switzerland

Kathryn Chapman     National Centre for the Replacement, Refinement and Reduction of Animals in Research (NC3Rs), London, United Kingdom

Gary J. Chellman     Charles River Laboratories, Reno, NV, USA

Timothy P. Coogan     Janssen Research and Development, LLC, Spring House, PA, USA

Jessica Couch     Genentech, South San Francisco, CA, USA

Lolke de Haan     Medimmune, Cambridge, United Kingdom

Thierry Decelle     Sanofi Pasteur, Marcy L’Etoile, France

Annie Delaunois     Non-Clinical Development, UCB Biopharma SPRL, Braine-l’Alleud, Belgium

Raffaella Faggioni     Clinical Pharmacology & DMPK, MedImmune LLC, Mountain View, CA, USA

Betsy Ferguson     Oregon Health & Sciences University and Oregon National Primate Research Center, Beaverton, OR, USA

John Finch     Charles River Laboratories, Edinburgh, United Kingdom

Virginia Fisher     Huntingdon Life Sciences Ltd, Huntingdon, United Kingdom

Werner Frings     Chugai Pharmaceutical Co., Ltd., Gotemba, Japan

Thomas Gelzleichter     Genentech, South San Francisco, CA, USA

Andreas Gschwind     Center for Integrative Genomics, University of Lausanne, Lausanne, Switzerland

Robert Hall     Covance Laboratories Inc., Madison, WI, USA

Wendy G. Halpern     Genentech, South San Francisco, CA, USA

Tobias Heckel     F. Hoffmann–La Roche Ltd, Pharma Research & Early Development, Basel, Switzerland

Kristin L. Henson     Novartis Institutes for Biomedical Research, East Hanover, NJ, USA

Susan Henwood     Covance, Madison, WI, USA

Jonathan R. Heyen     Pfizer La Jolla, San Diego, CA, USA

William Oliver Iverson     MedImmune, Gaithersburg, MD, USA

Mary Jeanne Kallman     Covance Laboratories, Greenfield, IN, USA

Joachim Kaspareit     Covance Laboratories, Münster, Germany

Tina Koban     Huntingdon Life Sciences, Huntingdon, United Kingdom

Sven Korte     Covance Laboratories GmbH, Münster, Germany

Pierre Lainée     Animal Welfare and Research, Sanofi, Montpellier, France

Michael W. Leach     Pfizer, Inc., Andover, MA, USA

Lynne LeSauteur     Human Health Therapeutics, National Research Council, Montreal, QC, Canada

Anne D. Lewis     Oregon National Primate Research Center, Oregon Health and Science University, Beaverton, OR, USA

Beatriz Silva Lima     iMED.ULisboa, Universidade de Lisboa, Faculty of Pharmacy, Lisboa, Portugal

Yanfei L. Ma     Lilly Research Laboratories, Indianapolis, IN, USA

Keith G. Mansfield     Novartis Institutes for Biomedical Research, Inc., Cambridge, MA, USA

C. Marc Luetjens     Covance Laboratories GmbH, Münster, Germany

Pauline L. Martin     Janssen Research and Development, LLC, Spring House, PA, USA

Kerstin Mätz-Rensing     German Primate Center, Göttingen, Germany

Lars Fris Mikkelsen     Independent

Barbara Mounho-Zamora     ToxStrategies, Inc., Bend, OR, USA

Wolfgang Müller     Covance, Münster, Germany

Dennis J. Murphy     GlaxoSmithKline Pharmaceuticals, King of Prussia, PA, USA

Marc Niehoff     Covance Münster, Germany

Birgit Niggemann     Covance Laboratories GmbH, Münster, Germany

Helen Palmer     Huntingdon Life Sciences Ltd, Huntingdon, United Kingdom

Daniel J. Patrick     MPI Research, Mattawan, MI, USA

Christopher Peters     UCB Biopharma, New Medicine, Non-Clinical Development, Braine L’Alleud, Belgium

Marie-Soleil Piché     Charles River Laboratories, Senneville, QC, Canada

Mark Prescott     National Centre for the Replacement, Refinement and Reduction of Animals in Research (NC3Rs), London, United Kingdom

Kamm Prongay     Oregon National Primate Research Center, Oregon Health and Science University, Beaverton, OR, USA

Marlon C. Rebelatto     MedImmune, Biologics Safety Assessment, Gaithersburg, MD, USA

Alexandre Reymond     Center for Integrative Genomics, University of Lausanne, Lausanne, Switzerland

Laura Richman     Translational Sciences, MedImmune, Gaithersburg, MD, USA

Christian Roos     Gene Bank of Primates and Primate Genetics Laboratory, German Primate Center, Leibniz Institute for Primate Research, Göttingen, Germany

Lorin K. Roskos     Clinical Pharmacology & DMPK, MedImmune LLC, Mountain View, CA, USA

Chandrassegar Saravanan     Novartis Institutes for Biomedical Research, Inc., Cambridge, MA, USA

Vito G. Sasseville     Novartis Institutes for Biomedical Research, Inc., Cambridge, MA, USA

Emanuel Schenck     MedImmune, Gaithersburg, MD, USA

Georg Schmitt     F. Hoffmann-La Roche Ltd., Basel, Switzerland

Jacintha M....

Produkt-Details

• Erscheint lt. Verlag: 13.3.2015
• Sprache: englisch
• Themenwelt: Medizin / Pharmazie ► Gesundheitsfachberufe
• Themenwelt: Medizin / Pharmazie ► Medizinische Fachgebiete ► Pharmakologie / Pharmakotherapie
• Themenwelt: Studium ► 2. Studienabschnitt (Klinik) ► Pharmakologie / Toxikologie
• ISBN-10: 0-12-417146-X / 012417146X
• ISBN-13: 978-0-12-417146-6 / 9780124171466